Aberrant methylation of APC, MGMT, RASSF2A, and Wif-1 genes in plasma as a biomarker for early detection of colorectal cancer

Clinical Cancer Research

Volumn 15, Issue 19, 2009, Pages 6185-6191

  Bo, Bin Lee ^a   Eun, Ju Lee ^a   Eun, Hyun Jung ^a   Chun, Ho Kyung ^a   Dong, Kyoung Chang ^a   Sang, Yong Song ^a   Park, Joobae ^a   Kim, Duk Hwan ^a  

^a Samsung Medical Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; CARRIER PROTEINS AND BINDING PROTEINS; DEATH ASSOCIATED PROTEIN KINASE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN MLH1; PROTEIN P14; PROTEIN P16; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 2A; RETINOIC ACID RECEPTOR BETA; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER TISSUE; COLORECTAL ADENOMA; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DNA METHYLATION; EARLY DIAGNOSIS; EPIGENETICS; FEMALE; GENE; GENETIC MARKER; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MUCINOUS CARCINOMA; PRIORITY JOURNAL; WIF 1 GENE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOMA; AGED; COLORECTAL NEOPLASMS; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; EARLY DETECTION OF CANCER; FEMALE; GENES, APC; HUMANS; MALE; MIDDLE AGED; PLASMA; PROTEIN ISOFORMS; REPRESSOR PROTEINS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 70349656779     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-0111     Document Type: Article

References (31)

1. Smith RA, Cokkinides V, Eyre HJ. American Cancer Society guidelines for the early detection of cancer, 2006. CA Cancer J Clin 2006; 56:11-25. (Pubitemid 43228384)
2. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 1998;72:141-196
3. Kondo Y, Issa J-PJ. Epigenetic changes in colorectal cancer. Cancer Metastasis Rev 1999;18:65-73.
4. GradyWM, Rajput A, Lutterbaugh JD,Markowitz SD. Detection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer. Cancer Res 2001;61:900-902
5. Zou HZ, Yu BM, Wang ZW, et al. Detection of aberrant p16 methylation in the serum of colorectal cancer patients. Clin Cancer Res 2002;8:188-191 (Pubitemid 34101476)
6. Nakayama H, Hibi K, Taguchi M, et al. Molecular detection of p16 promoter methylation in the serum of colorectal cancer patients. Cancer Lett 2002;188:115-119 (Pubitemid 35292337)
7. Yamaguchi S, Asao T, Nakamura J, Ide M, Kuwano H. High frequency of DAP-kinase gene promoter methylation in colorectal cancer specimens and its identification in serum. Cancer Lett 2003;194:99-105. (Pubitemid 36428889)
8. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996;93:9821-9826
9. Lee EJ, Lee BB, Han J, et al. CpG island hypermethylation of E-cadherin (CDH1) and integrin α4 is associated with recurrence of early stage esophageal squamous cell carcinoma. Int J Cancer 2008;123:2073-2079
10. Kim YH, Petko Z, Dzieciatkowski S, et al. CpG island methylation of genes accumulates during the adenoma progression step of the multistep pathogenesis of colorectal cancer. Genes Chromosomes Cancer 2006;45:781-789
11. Hesson LB, Wilson R, Morton D, et al. CpG island promoter hypermethylation of a novel Raseffector gene RASSF2A is an early event in colon carcinogenesis and correlates inversely with K-ras mutations. Oncogene 2005;24:3987-3994 (Pubitemid 40896410)
12. Enokida H, Shiina H, Urakami S, et al. Multigene methylation analysis for detection and staging of prostate cancer. Clin Cancer Res 2005;11:6582-6588 (Pubitemid 41338998)
13. Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer 2003;3: 253-266
14. Issa JP, Ahuja N, Toyota M, Bronner MP, Brentnall TA. Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res 2001;61:3573-3577 (Pubitemid 32694963)
15. Nakagawa H, Nuovo GJ, Zervos EE, et al. Agerelated hypermethylation of the 5′ region of MLH1 in normal colonic mucosa is associated with microsatellite-unstable colorectal cancer development. Cancer Res 2001;61:6991-6995 (Pubitemid 32946483)
16. Shen L, Kondo Y, Hamilton SR, Rashid A, Issa JP. P14 methylation in human colon cancer is associated with microsatellite instability and wildtype p53. Gastroenterology 2003;124:626-633 (Pubitemid 36268481)
17. Kawakami K, Ruszkiewicz A, Bennett G, et al. DNA hypermethylation in the normal colonic mucosa of patients with colorectal cancer. Br J Cancer 2006;94:593-598 (Pubitemid 43289765)
18. Esteller M, Sparks A, Toyota M, et al. Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res 2000;60:4366-4371 (Pubitemid 32103613)
19. Bai AH, Tong JH, To KF, et al. Promoter hypermethylation of tumor-related genes in the progression of colorectal neoplasia. Int J Cancer 2004;112:846-853 (Pubitemid 39435270)
20. Lee S, Hwang KS, Lee HJ, Kim JS, Kang GH. Aberrant CpG island hypermethylation of multiple genes in colorectal neoplasia. Lab Invest 2004;84:884-893 (Pubitemid 38833248)
21. Judson H, Stewart A, Leslie A, et al. Relationship between point gene mutation, chromosomal abnormality, and tumour suppressor gene methylation status in colorectal adenomas. J Pathol 2006;210:344-350 (Pubitemid 44660513)
22. Petko Z, Ghiassi M, Shuber A, et al. Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps. Clin Cancer Res 2005;11:1203-1209
23. Shen L, Kondo Y, Rosner GL, et al. MGMT promoter methylation and field defect in sporadic colorectal cancer. JNatl Cancer Inst 2005;97:1330-1338 (Pubitemid 41487800)
24. Akino K, Toyota M, Suzuki H, et al. The Ras effector RASSF2 is a novel tumor-suppressor gene in human colorectal cancer. Gastroenterology 2005;129:156-169 (Pubitemid 41002052)
25. Park HW, Kang HC, Kim IJ, et al. Correlation between hypermethylation of the RASSF2A promoter and K-ras/BRAF mutations in microsatellite-stable colorectal cancers. Int J Cancer 2007; 120:7-12.
26. BelshawNJ, Elliott GO, Foxall RJ, et al. Profiling CpG island field methylation in both morphologically normal and neoplastic human colonic mucosa. Br J Cancer 2008;99:136-142
27. Taniguchi H, Yamamoto H, Hirata T, et al. Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers. Oncogene 2005;24:7946-7952 (Pubitemid 41715201)
28. Giacona MB, Ruben GC, Iczkowski KA, Roos TB, Porter DM, Sorenson GD. Cell-free DNA in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls. Pancreas 1998;17:89-97.
29. Wu TL, Zhang D, Chia JH, Tsao KH, Sun CF, Wu JT. Cell-free DNA: measurement in various carcinomas and establishment of normal reference range. Clin Chim Acta 2002;321: 77-87. (Pubitemid 34597056)
30. ShawRJ, Akufo-Tetteh EK, Risk JM, Field JK, Liloglou T. Methylation enrichment pyrosequencing: combining the specificity of MSP with validation by pyrosequencing. Nucleic Acids Res 2006;34:e78.
31. Kawamoto K, Enokida H, Gotanda T, et al. p16INK4a and p14ARF methylation as a potential biomarker for human bladder cancer. Biochem Biophys Res Commun 2006;399: 790-796 (Pubitemid 41772883)